PURPOSE: To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML). PATIENTS AND METHODS: Available diagnostic marrow specimens (n = 790) from 1,328 patients enrolled in three consecutive Children's Cancer Group/Children's Oncology Group trials were analyzed for the presence of SNP rs16754. SNP status was correlated with disease characteristics, WT1 expression level, and clinical outcome. RESULTS: SNP rs16754 was present in 229 (29%) of 790 patients. The SNP was significantly more common in Asian and Hispanic patients and less common in white patients (P < .001). SNP rs16754 was also less common in patients with inv(16) (P = .043) and more common in patients with -5/del(5q) (P = .047). WT1 expression levels were significantly higher in patients with rs16754 or with WT1 mutations compared with WT1 wild-type patients (P = .021). Five-year overall survival (OS) for patients with and without the SNP was 60% and 50%, respectively (P = .031). Prognostic assessment by risk group demonstrated that in patients with low-risk disease, OS for those with and without SNP rs16754 was 90% versus 64% (P < .001) with a corresponding disease-free survival of 72% versus 53% (P = .041). CONCLUSION: The presence of SNP rs16754 was an independent predictor of improved OS; outcome differences were most pronounced in the low-risk subgroup. The high prevalence of WT1 SNP rs16754, and its correlation with improved outcome, identifies WT1 SNP rs16754 as a potentially important molecular marker of prognosis in pediatric AML.
PURPOSE: To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML). PATIENTS AND METHODS: Available diagnostic marrow specimens (n = 790) from 1,328 patients enrolled in three consecutive Children's Cancer Group/Children's Oncology Group trials were analyzed for the presence of SNP rs16754. SNP status was correlated with disease characteristics, WT1 expression level, and clinical outcome. RESULTS: SNP rs16754 was present in 229 (29%) of 790 patients. The SNP was significantly more common in Asian and Hispanic patients and less common in white patients (P < .001). SNP rs16754 was also less common in patients with inv(16) (P = .043) and more common in patients with -5/del(5q) (P = .047). WT1 expression levels were significantly higher in patients with rs16754 or with WT1 mutations compared with WT1 wild-type patients (P = .021). Five-year overall survival (OS) for patients with and without the SNP was 60% and 50%, respectively (P = .031). Prognostic assessment by risk group demonstrated that in patients with low-risk disease, OS for those with and without SNP rs16754 was 90% versus 64% (P < .001) with a corresponding disease-free survival of 72% versus 53% (P = .041). CONCLUSION: The presence of SNP rs16754 was an independent predictor of improved OS; outcome differences were most pronounced in the low-risk subgroup. The high prevalence of WT1 SNP rs16754, and its correlation with improved outcome, identifies WT1 SNP rs16754 as a potentially important molecular marker of prognosis in pediatric AML.
Authors: Chava Kimchi-Sarfaty; Jung Mi Oh; In-Wha Kim; Zuben E Sauna; Anna Maria Calcagno; Suresh V Ambudkar; Michael M Gottesman Journal: Science Date: 2006-12-21 Impact factor: 47.728
Authors: Phoenix A Ho; Rong Zeng; Todd A Alonzo; Robert B Gerbing; Kristen L Miller; Jessica A Pollard; Derek L Stirewalt; Nyla A Heerema; Susana C Raimondi; Betsy Hirsch; Janet L Franklin; Beverly Lange; Soheil Meshinchi Journal: Blood Date: 2010-04-22 Impact factor: 22.113
Authors: Daniela Cilloni; Aline Renneville; Fabienne Hermitte; Robert K Hills; Sarah Daly; Jelena V Jovanovic; Enrico Gottardi; Milena Fava; Susanne Schnittger; Tamara Weiss; Barbara Izzo; Josep Nomdedeu; Adrian van der Heijden; Bert A van der Reijden; Joop H Jansen; Vincent H J van der Velden; Hans Ommen; Claude Preudhomme; Giuseppe Saglio; David Grimwade Journal: J Clin Oncol Date: 2009-09-14 Impact factor: 44.544
Authors: Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan Journal: Haematologica Date: 2012-04 Impact factor: 9.941
Authors: Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn Journal: Int J Cancer Date: 2012-04-04 Impact factor: 7.396
Authors: Heiko Becker; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Klaus H Metzeler; Susan P Whitman; Sebastian Schwind; Jessica Kohlschmidt; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Guido Marcucci; Clara D Bloomfield Journal: Haematologica Date: 2011-06-09 Impact factor: 9.941
Authors: Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica A Pollard; Betsy Hirsch; Susana C Raimondi; Todd Cooper; Alan S Gamis; Soheil Meshinchi Journal: Br J Haematol Date: 2013-07-04 Impact factor: 6.998
Authors: Anne-Sophie Junghanns; Susan Wittig; Caroline Woehlecke; Thomas Lehmann; Clemens Arndt; Bernd Gruhn Journal: J Cancer Res Clin Oncol Date: 2015-07-30 Impact factor: 4.553